These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 24789001

  • 1. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries.
    Cantini F, Niccoli L, Goletti D.
    J Rheumatol Suppl; 2014 May; 91():56-64. PubMed ID: 24789001
    [Abstract] [Full Text] [Related]

  • 2. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review.
    Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostör AJ.
    Rheumatology (Oxford); 2011 Dec; 50(12):2297-305. PubMed ID: 22019799
    [Abstract] [Full Text] [Related]

  • 3. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance.
    Cantini F, Niccoli L, Goletti D.
    J Rheumatol Suppl; 2014 May; 91():47-55. PubMed ID: 24789000
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L, Lapadula G, Mathieu A.
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [Abstract] [Full Text] [Related]

  • 5. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL, Valesini G.
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP, Buckley F, Dejonckheere F, Ogale S.
    Health Qual Life Outcomes; 2014 Jul 03; 12():102. PubMed ID: 24988902
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, Carreño L, Figueroa M, BIOBADASER Group.
    Arthritis Rheum; 2005 Jun 03; 52(6):1766-72. PubMed ID: 15934089
    [Abstract] [Full Text] [Related]

  • 8. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G.
    BioDrugs; 2014 Apr 03; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [Abstract] [Full Text] [Related]

  • 9. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK, Rafiq A, Östör AJ.
    Clin Rheumatol; 2015 Dec 03; 34(12):2141-5. PubMed ID: 26497501
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapies in rheumatologic disorders.
    Miller AV, Ranatunga SK.
    Med Clin North Am; 2012 May 03; 96(3):475-96, ix-x. PubMed ID: 22703852
    [Abstract] [Full Text] [Related]

  • 11. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
    Aletaha D.
    BioDrugs; 2014 Apr 03; 28 Suppl 1():S3-4. PubMed ID: 24687233
    [No Abstract] [Full Text] [Related]

  • 12. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL, Cohen PR.
    Int J Dermatol; 2011 May 03; 50(5):619-25. PubMed ID: 21506984
    [Abstract] [Full Text] [Related]

  • 13. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H, Horiuchi T, Tsukamoto H, Ueda N.
    Cytokine; 2018 Jan 03; 101():56-63. PubMed ID: 27567553
    [Abstract] [Full Text] [Related]

  • 14. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
    Lorenzetti R, Zullo A, Ridola L, Diamanti AP, Laganà B, Gatta L, Migliore A, Armuzzi A, Hassan C, Bruzzese V.
    Ann Med; 2014 Nov 03; 46(7):547-54. PubMed ID: 25105206
    [Abstract] [Full Text] [Related]

  • 15. The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-α Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies.
    Ai JW, Zhang S, Ruan QL, Yu YQ, Zhang BY, Liu QH, Zhang WH.
    J Rheumatol; 2015 Dec 03; 42(12):2229-37. PubMed ID: 26472414
    [Abstract] [Full Text] [Related]

  • 16. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries.
    Mariette X, Gottenberg JE, Ravaud P, Combe B.
    Rheumatology (Oxford); 2011 Jan 03; 50(1):222-9. PubMed ID: 21148156
    [Abstract] [Full Text] [Related]

  • 17. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.
    Rheumatology (Oxford); 2015 Apr 03; 54(4):601-8. PubMed ID: 25231180
    [Abstract] [Full Text] [Related]

  • 18. [New biologic and non biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis].
    Saito K, Tanaka Y.
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun 03; 32(3):149-59. PubMed ID: 19564711
    [Abstract] [Full Text] [Related]

  • 19. The risk of tuberculosis in patients treated with TNF antagonists.
    Salgado E, Gómez-Reino JJ.
    Expert Rev Clin Immunol; 2011 May 03; 7(3):329-40. PubMed ID: 21595599
    [Abstract] [Full Text] [Related]

  • 20. [Certolizumab pegol].
    Delgado Frías E, Díaz González JF.
    Reumatol Clin; 2011 Mar 03; 6S3():S7-11. PubMed ID: 21794764
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.